ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.691,25
-0,58%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. PepGen Inc (PEPG)

  7. PepGen Inc (PEPG) News

PEPG

PepGen (PEPG)

PepGen Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PEPG
DatumZeitQuelleÜberschriftSymbolFirma
18/05/202402h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
17/05/202422h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
14/05/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
14/05/202422h02GlobeNewswire Inc.PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
14/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
13/03/202421h05GlobeNewswire Inc.PepGen to Participate in Upcoming Investor ConferencesNASDAQ:PEPGPepGen Inc
13/03/202412h00GlobeNewswire Inc.PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
06/03/202422h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PEPGPepGen Inc
06/03/202422h01GlobeNewswire Inc.PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
06/03/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
04/03/202413h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
04/03/202413h00GlobeNewswire Inc.PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
01/03/202423h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
01/03/202423h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
01/03/202423h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
20/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
20/02/202414h00GlobeNewswire Inc.PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
07/02/202422h55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PEPGPepGen Inc
07/02/202413h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
07/02/202413h30GlobeNewswire Inc.PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockNASDAQ:PEPGPepGen Inc
17/01/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
17/01/202413h00GlobeNewswire Inc.Mary Beth DeLena Joins PepGen as General Counsel and SecretaryNASDAQ:PEPGPepGen Inc
08/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
08/01/202413h00GlobeNewswire Inc.PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingNASDAQ:PEPGPepGen Inc
18/12/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
18/12/202314h00GlobeNewswire Inc.PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)NASDAQ:PEPGPepGen Inc
15/11/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
15/11/202314h00GlobeNewswire Inc.PepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsNASDAQ:PEPGPepGen Inc
08/11/202314h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
08/11/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
 Showing the most relevant articles for your search:NASDAQ:PEPG

Kürzlich von Ihnen besucht

COIN
AOGGUST
AgeOfGods
LATK
TKOUSDT
Tokocrypto Token
NASDAQ
TXICU
ASX
TTVN
USOTC
CEXE
Circle Entertainment (CE)
LSE
EME
Empyrean Energy
BITMOT
881696
World Bank Green Tf 4,25...
NASDAQ
SLNAW
Selina Hospitality
COIN
EUROPEUR
LSE
XLF3
3x Financials
BIT
XGII
Db X-tr Ii Gl Inf Linked...
DBI
4N8Z
DAXsubsector All Home Co...
AMEX
BPW
EU
XS1396367911
Enexis Holding NV 0.875%...
BOV
BBASE497
BBASE497 Ex:24,34
LATK
PATHUSDT
Path Network Token
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten